---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-026140"
form_type: "8-K/A"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:47:14.484136+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics completes acquisition of AlmataBio; discloses audited financials and pro forma info

## Summary
- AlmataBio net loss of $659k from inception (April 28, 2023) to Dec 31, 2023; cash $1.8M, total assets $1.8M.
- Acquired anti-IL-1β asset (AVTX-009) from Leap Therapeutics for $500k cash plus potential milestones up to $70M development/regulatory and $720M sales-based.
- Deal closed March 27, 2024, structured as stock-for-stock: AlmataBio equity exchanged for Avalo common and non-voting convertible preferred stock.
- Unaudited pro forma combined statements for year ended Dec 31, 2023 and Q1 2024 filed as Exhibit 99.2.

## SEC filing metadata
- accession: 0001628280-24-026140
- form_type: 8-K/A
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024026140/0001628280-24-026140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024026140/avtx-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-026140
- JSON: https://secwatch.observer/filing/0001628280-24-026140.json
- Plain text: https://secwatch.observer/filing/0001628280-24-026140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.